TransMedics Group, Inc. Common Stock
TMDX
$101.26
-6.34%
TransMedics Group, Inc. is a commercial-stage medical technology company focused on transforming organ transplant therapy through its proprietary Organ Care System (OCS). The company is a clear market leader and disruptor in the field of portable organ perfusion, offering a technology that preserves donor organs in a near-physiologic state, addressing significant limitations of traditional cold storage. The current investor narrative is dominated by the company's transition to robust profitability and explosive revenue growth, as evidenced by its latest quarterly results, though recent stock price volatility suggests the market is grappling with valuation concerns after a period of exceptional performance.…
TMDX
TransMedics Group, Inc. Common Stock
$101.26
Investment Opinion: Should I buy TMDX Today?
Rating & Thesis: Hold. TMDX is a compelling but richly valued growth story caught between stellar fundamentals and a punishing technical/multiple compression trend. The consensus analyst sentiment is bullish, but the stock's severe underperformance and high volatility warrant caution until the valuation resets or growth re-accelerates convincingly.
Supporting Evidence: The Hold rating is supported by four key data points: 1) Accelerating revenue growth of 32.2% YoY, 2) A transition to strong cash generation with $133.6M in TTM FCF, 3) A premium but compressed trailing P/E of 21.73x (down from over 39x in Q3 2025), and 4) A high short ratio of 7.66 that could provide fuel for a rally on positive news. However, the forward P/E of 30.12x suggests earnings normalization post the tax benefit, and the P/S of 6.8x is high relative to most medical device peers.
Risks & Conditions: The two biggest risks are growth deceleration and continued multiple compression. This Hold would upgrade to a Buy if the stock sustains a break above $140 (signaling a technical reversal) and/or if the forward P/E compresses to the low-20s while growth remains above 25%. It would downgrade to a Sell if revenue growth decelerates below 15% or if the stock breaks decisively below its 52-week low support near $88.5. Currently, the stock is fairly valued to slightly overvalued given the high growth but substantial execution and market risks.
Sign up to view all
TMDX 12-Month Price Forecast
The outlook for TMDX is a battle between its fundamentally strong, cash-generative growth and a market unwilling to pay previous premium multiples. The base case (50% probability) of range-bound trading is most likely, as the company executes well but struggles to regain its former valuation zenith in the current environment. The high short interest and low analyst coverage add layers of uncertainty and potential volatility. The stance would upgrade to bullish on evidence of sustained >30% growth and a technical reclaim of the $140 level. It would turn bearish on a breakdown below $88.5 or a material growth slowdown.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on TransMedics Group, Inc. Common Stock's 12-month outlook, with a consensus price target around $131.64 and implied upside of +30.0% versus the current price.
Average Target
$131.64
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$81 - $132
Analyst target range
Analyst coverage appears limited with only 3 analysts providing estimates, though institutional ratings data shows ongoing coverage from several major firms. The consensus sentiment is bullish, with recent actions from firms like Piper Sandler, Oppenheimer, Evercore ISI, and Needham maintaining 'Outperform' or 'Buy' ratings, while Stifel and JP Morgan maintain a 'Hold' or 'Neutral' stance. The average revenue estimate for the next period is $1.215 billion, with a tight range between $1.204 billion and $1.231 billion, indicating strong consensus on the near-term growth trajectory. The wide dispersion in recent stock price targets is not provided in the data, but the minimal number of analysts providing formal estimates suggests that while institutional interest is present, comprehensive consensus targets may be sparse, which can contribute to higher volatility as the market seeks to price the company's new phase of profitable growth.
Bulls vs Bears: TMDX Investment Factors
The investment debate for TMDX centers on the tension between its exceptional fundamental growth story and its demanding valuation in a market that is punishing high-multiple stocks. The bull case is powerfully supported by accelerating 32% revenue growth, a clear inflection to cash generation, and robust gross margins. However, the bear case is equally compelling, citing a severe technical breakdown, extreme volatility (beta 2.08), and valuation multiples (30x forward P/E) that leave no margin for safety. Currently, the bearish technical and valuation evidence appears stronger, as the stock's 18% three-month decline and high short interest reflect market skepticism about sustaining the premium. The single most important factor is whether revenue growth can continue accelerating or at least hold above 30% to justify its sales multiple of 6.8x. A deceleration below 20% would likely trigger further multiple compression, while sustained hyper-growth could fuel a sharp short-covering rally.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue grew 32.2% year-over-year to $160.8 million, accelerating from 21.6% growth in Q3. This demonstrates strong and increasing demand for the OCS platform, a key driver for a growth stock.
- Profitable Growth Inflection: The company reported net income of $105.4 million in Q4 2025, achieving a net margin of 31.4%. More sustainably, trailing twelve-month free cash flow is a robust $133.6 million, confirming the transition to a self-funding, profitable enterprise.
- Strong Balance Sheet & Returns: Financial health is excellent with a current ratio of 7.14 and a manageable debt-to-equity of 0.99. The return on equity of 40.2% is outstanding, indicating highly efficient use of capital in its growth phase.
- High Gross Margins: Gross margin for Q4 2025 was 58.1%, consistent with the trailing gross margin of 59.9%. This demonstrates significant pricing power and a profitable business model for its disruptive medical technology.
Bearish
- Valuation Compression & High Multiples: Despite a recent pullback, valuation remains elevated with a forward P/E of 30.12x and a P/S ratio of 6.83x. These multiples are high for the medical device sector and suggest little room for error if growth decelerates.
- Severe Technical Downtrend: The stock is down 18.01% over the last three months and 15.01% over six months, significantly underperforming the S&P 500. Trading 29% below its 52-week high indicates broken momentum and persistent selling pressure.
- Extreme Volatility & High Short Interest: A beta of 2.08 means the stock is more than twice as volatile as the market. A short ratio of 7.66 indicates significant bearish sentiment, which can exacerbate downside moves and limit upside until proven wrong.
- Q4 Profitability Boosted by One-Time Item: The impressive Q4 2025 net income of $105.4 million was significantly inflated by an $83.75 million income tax benefit. This non-recurring item distorts the true operating profitability, as evidenced by the operating margin of 17.9%.
TMDX Technical Analysis
The stock is in a pronounced downtrend over the past six months, with a price decline of 15.01% and a more severe 18.01% drop over the last three months, significantly underperforming the broader market. Currently trading at $110.93, the price sits approximately 29% above its 52-week low of $88.5 and 29% below its 52-week high of $156.0, positioning it in the lower-middle of its annual range, which suggests the momentum has broken down but may not yet represent deep-value territory. Recent momentum shows a stark divergence, with a 5.52% gain over the past month contrasting sharply with the longer-term declines, indicating a potential near-term relief rally or consolidation within the broader downtrend, though the 1-year gain of 17.79% remains positive. Key technical support is clearly defined at the 52-week low area near $88.5, while resistance lies at the recent highs around $156; a sustained break below support would signal a continuation of the bearish trend, whereas reclaiming the $140-$150 zone would be necessary to suggest a reversal. The stock's beta of 2.08 indicates it is more than twice as volatile as the market, a critical factor for risk management, and the elevated short ratio of 7.66 points to significant bearish sentiment that could fuel sharp rallies on any positive catalyst.
Beta
2.08
2.08x market volatility
Max Drawdown
-37.3%
Largest decline past year
52-Week Range
$89-$156
Price range past year
Annual Return
+12.3%
Cumulative gain past year
| Period | TMDX Return | S&P 500 |
|---|---|---|
| 1m | +2.2% | +12.2% |
| 3m | -28.2% | +2.3% |
| 6m | -25.4% | +4.7% |
| 1y | +12.3% | +29.2% |
| ytd | -17.5% | +4.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMDX Fundamental Analysis
Revenue growth is exceptionally strong, with Q4 2025 revenue of $160.8 million representing a 32.2% year-over-year increase, continuing an accelerating multi-quarter trend from 21.6% YoY growth in Q3. The company has achieved a remarkable inflection to profitability, reporting net income of $105.4 million in Q4, driven significantly by a one-time income tax benefit, with a robust gross margin of 58.1% demonstrating solid pricing power for its OCS technology. Profitability metrics have improved dramatically, as evidenced by a net margin of 31.4% for the latest quarter (though inflated by the tax benefit) and a trailing twelve-month free cash flow of $133.6 million, indicating the business is now generating substantial cash from operations. The balance sheet is healthy with a strong current ratio of 7.14 and a manageable debt-to-equity ratio of 0.99, while the return on equity of 40.2% is outstanding, though partially amplified by financial leverage and the large net income figure; the company's financial health has transformed, moving from a cash-burning growth story to a self-funding, profitable enterprise.
Quarterly Revenue
$160764000.0B
2025-12
Revenue YoY Growth
+0.32%
YoY Comparison
Gross Margin
+0.58%
Latest Quarter
Free Cash Flow
$133589000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMDX Overvalued?
Given the company's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E stands at 21.73x, while the forward P/E is higher at 30.12x, indicating the market expects earnings to decline from the elevated Q4 level, which included a large non-recurring tax benefit. Compared to its own historical range, the current trailing P/E of 21.73x is below the levels seen in mid-2025 (e.g., 32.55x in Q2 2025 and 39.35x in Q3 2025) but above the 9.88x recorded at the end of Q4 2025, suggesting the valuation has compressed from peak optimism but remains above the most recent quarter's depressed multiple. The price-to-sales ratio of 6.83x and EV/Sales of 6.47x are high for a medical device company, reflecting a premium for the company's disruptive technology and hyper-growth profile, though this premium is being tested as growth rates potentially normalize and the stock corrects from its highs.
PE
21.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -683x~311x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is valuation dependency on continued hyper-growth, as a forward P/E of 30.12x and P/S of 6.83x are unsustainable if revenue growth decelerates from the current 32% rate. While profitability has improved, Q4's net margin of 31.4% was inflated by an $83.75 million one-time tax benefit, masking a more modest operating margin of 17.9%. The company also carries a debt-to-equity ratio of 0.99, which, while manageable, introduces financial leverage risk if interest rates remain elevated or cash flow generation stalls.
Market & Competitive Risks: The stock faces acute valuation compression risk, having already declined 29% from its 52-week high as the market reappraises growth stock premiums. Its beta of 2.08 indicates extreme sensitivity to broader market swings, particularly negative sentiment towards high-multiple healthcare technology stocks. Competitive risks, while not detailed in the data, are inherent as the organ transplant market attracts new entrants, and any technological advancement or pricing pressure could challenge TMDX's premium pricing power evidenced by its 58% gross margin.
Worst-Case Scenario: The worst-case scenario involves a combination of growth deceleration below 20%, a broader market sell-off impacting high-beta stocks, and a short squeeze failing to materialize due to lack of catalysts. This could trigger a re-rate to valuation levels seen at its 52-week low. From the current price of $110.93, a decline to the 52-week low of $88.5 represents a potential loss of approximately -20%. A more severe scenario, factoring in the stock's 37.3% maximum drawdown, suggests a theoretical downside to around $69, representing a loss of over -38% from current levels.
FAQ
The key risks are: 1) Valuation & Multiple Compression: High forward P/E (30.12x) and P/S (6.83x) are vulnerable if growth slows. 2) Extreme Volatility: A beta of 2.08 means the stock is more than twice as volatile as the market. 3) Growth Dependency: The investment thesis relies entirely on sustaining hyper-growth (currently 32%); deceleration would severely impact the stock. 4) Competitive/Regulatory: As a market leader in a niche, it faces potential competition and regulatory scrutiny. The high short interest (short ratio 7.66) also adds technical risk of amplified moves.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees the stock trading between $115 and $140 as growth moderates but remains strong and valuation stabilizes. The Bull Case (25% probability) projects a return to the 52-week high of $156 or above, driven by sustained >30% growth and a short squeeze. The Bear Case (25% probability) warns of a drop to the $88-$105 range if growth decelerates sharply. The most likely outcome is the Base Case, assuming the company executes its growth plan without major setbacks but fails to re-rate to prior premium multiples.
TMDX is fairly valued to slightly overvalued based on current metrics. Its forward P/E of 30.12x and P/S ratio of 6.83x command a significant premium, typical for a hyper-growth story but high for the medical device sector. However, the valuation has compressed from much higher levels (P/E was 39.35x in Q3 2025). The market is pricing in continued high growth; thus, it is not deeply undervalued. The stock is fairly valued only if it can sustain >25% growth and expand margins. Any growth disappointment would likely make it overvalued at current prices.
TMDX is a high-risk, high-reward investment that may be a good buy for aggressive growth investors comfortable with volatility. The stock offers exposure to a company with 32% revenue growth and strong cash generation, but it trades at a premium forward P/E of 30x and has declined 18% in three months. The high short ratio of 7.66 could fuel a rally on positive news. It is not a good buy for conservative investors, but for those seeking disruptive medical tech growth and who can tolerate potential 20-30% drawdowns, it warrants a small, monitored position.
TMDX is primarily a long-term investment (3-5 years) for investors betting on the global adoption of its OCS technology. Its high beta of 2.08 and lack of dividend make it poorly suited for short-term trading or income. The long-term horizon allows time for the company to execute its growth strategy and for volatility to smooth out. However, given the current technical downtrend and valuation uncertainty, a short-term trade is highly speculative. The minimum suggested holding period is 12-18 months to assess whether the growth trajectory remains intact.